NEW YORK, Dec. 29, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Samarco Mineração S.A.’s 10-year notes respectively due 2022, 2023, and 2024 (collectively, the “Notes”) from October 31, 2012 through November 30, 2015, both dates inclusive (the “Class Period”) of the important January 13, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Samarco investors under the federal securities laws.
To join the Samarco class action, go to http://www.rosenlegal.com/cases-994.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Samarco’s Fundão tailings dam had longstanding systemic and structural defects; (2) Samarco ignored repeated, reliable warnings regarding the condition of the Fundão tailings dam while representing to investors that it had mitigated the risk of a catastrophic accident as much as possible through “a combination of risk management, careful evaluation, experience and knowledge,”; and (3) as a result, defendants’ statements about Samarco’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis. On November 5, 2015, Samarco’s Fundão tailings dam burst. Subsequent investigations revealed that Samarco had disregarded safety concerns about the Fundão dam for years. When the truth about Samarco’s operations was revealed by the collapse of the Fundão dam and investigation into its causes, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 13, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-994.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 



